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Research
An increasing number of studies show that
humans are exposed to a large number of
perfluorinated chemicals (PFCs), including
perfluorooctane sulfonate (PFOS) (Calafat
et al. 2006b; Karrman et al. 2006b; Yeung
et al. 2006). Pooled serum from Australians
< 16 years of age (median age 11–13 years)
had equal or higher levels of several PFCs
compared with adults (Karrman et al. 2006a).
PFOS concentration in 2- to 12-year-old
children in the United States ranged between
6.7 and 515 ng/mL, and the mean concentra-
tion of PFOS and additional PFCs exceeded
those for adult and elderly populations
(Olsen et al. 2004). Exposure routes for chil-
dren therefore need to be assessed. 
The surfactant properties of perﬂuorinated
chemicals have made them desirable for exten-
sive use in fabric, leather, and apparel treat-
ment, in protection of food packaging and
paper products, and in ﬁre-extinguishing foam
and insecticides. The inertness and great heat
stability of these chemicals have also extended
their industrial use.
PFCs have been shown to be persistent, to
biomagnify, and to be transported into remote
regions (Giesy and Kannan 2001; Smithwick
et al. 2005; Tomy et al. 2004). They are
potentially toxic for the environment and
humans (3M 2003; Kennedy et al. 2004).
Several studies have reported the increase of
PFC levels in humans and wildlife up to the
late 1990s (Harada et al. 2004; Holmström
et al. 2004; Olsen et al. 2005b). Recent efforts
by authorities and manufacturing companies
to phase out the production and reduce emis-
sions of PFCs has not yet been observed as
declining environmental concentrations.
Prenatal as well as postnatal toxicity of
PFOS was observed in rat and mouse, includ-
ing increased liver weights, growth lags, and
delayed development (Lau et al. 2003;
Thibodeaux et al. 2003). Reduced weight
gain and delayed development were also
observed for perfluorooctanoic acid (PFOA)
(Lau et al. 2004). However, assessment of
risks for humans by extrapolating animal data
must take into consideration several unknown
pharmacokinetic parameters, such as species-
specific clearance (Hanhijärvi et al. 1982;
Organisation for Economic Co-operation and
Development 2002).
Prenatal exposure and transfer of several
PFCs through lactation has been confirmed
for humans. Cord blood concentrations of
PFOS were on average three times lower
(1.6–5.3 ng/mL) than the corresponding
maternal blood concentration from nonoccu-
pational-exposed Japanese women (Inoue
et al. 2004). A study on two human milk
samples from the United States was the ﬁrst
to show the presence of PFCs in human milk
(Kuklenyik et al. 2004). Recently So et al.
(2006) reported that low levels (10–592.6
pg/mL) of PFOS, PFOA, perfluorohexane
sulfonate (PFHxS), and perfluorononanoic
acid (PFNA) were found in human milk of
women living in China. There is to our
knowledge no information about the degree
of maternal PFCs transferred to the infant
through lactation. A cross-fostering study on
Sprague-Dawley rats indicated that PFOS is
transferred to pups through lactation with a
milk concentration 10–100 times lower than
the maternal serum concentration (Kuklenyik
et al. 2004). The concentration of PFOA in
rat’s milk was estimated to be 10 times lower
than the concentration in maternal plasma
(Hinderliter et al. 2005). The speciﬁc transfer
mechanisms are however not clear.
The objective of this study was to elucidate
the relationship between maternal PFC serum
levels and breast milk levels to better under-
stand the lactational transfer of PFCs. For this
purpose, matched individual milk and serum
samples from 12 Swedish primiparous women
were collected in 2004. In addition, the trend
in Swedish breast milk PFC concentrations
between 1996 and 2004 is also reported.
This is the ﬁrst report on the relationship of
PFCs in human maternal serum and milk
and the first temporal trend in breast milk
PFC levels. Included in this study were four
perﬂuoroalkylsulfonates (C4, C6, C8, C10),
one polyfluorinated sulfonate (C8), seven
perﬂuoroalkylcarboxylates (C6, C8, C9, C10,
C11, C12, C14) and perﬂuorooctanesulfon-
amide (PFOSA).
Materials and Methods
Samples. Individual milk and serum samples
from 12 women in Uppsala, Sweden, were
collected in 2004. Milk samples from 25–90
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BACKGROUND: Only limited data exist on lactation as an exposure source of persistent perﬂuorinated
chemicals (PFCs) for children.
OBJECTIVES: We studied occurrence and levels of PFCs in human milk in relation to maternal
serum together with the temporal trend in milk levels between 1996 and 2004 in Sweden.
Matched, individual human milk and serum samples from 12 primiparous women in Sweden were
analyzed together with composite milk samples (25–90 women/year) from 1996 to 2004.
RESULTS: Eight PFCs were detected in the serum samples, and ﬁve of them were also above the
detection limits in the milk samples. Perfluorooctanesulfonate (PFOS) and perfluorohexane-
sulfonate (PFHxS) were detected in all milk samples at mean concentrations of 0.201 ng/mL and
0.085 ng/mL, respectively. Perﬂuorooctanesulfonamide (PFOSA), perﬂuorooctanoic acid (PFOA),
and perﬂuorononanoic acid (PFNA) were detected less frequently. 
DISCUSSION: The total PFC concentration in maternal serum was 32 ng/mL, and the corresponding
milk concentration was 0.34 ng/mL. The PFOS milk level was on average 1% of the corresponding
serum level. There was a strong association between increasing serum concentration and increasing
milk concentration for PFOS (r2 = 0.7) and PFHxS (r2 = 0.8). PFOS and PFHxS levels in composite
milk samples were relatively unchanged between 1996 and 2004, with a total variation of 20 and
32% coefﬁcient of variation, respectively.
CONCLUSION: The calculated total amount of PFCs transferred by lactation to a breast-fed infant in
this study was approximately 200 ng/day. Lactation is a considerable source of exposure for infants,
and reference concentrations for hazard assessments are needed.
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(2007). doi:10.1289/ehp.9491 available via http://dx.doi.org/ [Online 28 November 2006]women were collected each year between 1996
and 2004 and pooled into an annual compos-
ite sample. Donors originated from four
regions in Sweden (Uppsala, Lund, Göteborg,
Lycksele). All samples were from primiparous
women and were collected in glass bottles dur-
ing the third week after delivery and stored in
plastic containers at –20°C. A summary of the
sample information, including age of donors
and number of pooled samples, is given in
Table 1. The local ethics committee approved
the design of this study, and informed consent
was obtained from the study participants.
Chemicals. We purchased ammonium
acetate [> 99%, for high-performance liquid
chromatography (HPLC)] from Fluka
(Steinheim, Germany), formic acid (98–100%)
from Scharlau (Barcelona, Spain), and
methanol (HPLC) from Labscan (Dublin,
Ireland). All water used was laboratory-
produced ultrapure water. Ammonium
hydroxide (25% in water) and sodium acetate
were purchased from Merck (Darmstadt,
Germany). Perﬂuorobutanesulfonate (PFBuS)
tetrabutylammonium salt (> 98%), PFOS
potassium salt (> 98%), perfluorodecanoic
acid (PFDA; > 97%), and perﬂuorohexanoic
acid (PFHxA; > 97%) were purchased from
Fluka. Perfluoroheptanoic acid (PFHpA;
99%), PFNA (97%), PFOA (96%), perﬂuoro-
decanesulfonate (PFDS) ammonium salt
[25% weight in 2-butoxyethanol (37%) in
water], perﬂuoroundecanoic acid (PFUnDA;
95%), and perfluorotetradecanoic acid
(PFTDA; 97%) were purchased from Aldrich
(Steinheim, Germany, and Milwaukee, WI,
USA). PFOSA (97%) and 7H-PFHpA (98%)
were purchased from ABCR (Karlsruhe,
Germany). 1H,1H,2H,2H-PFOS (THPFOS,
purity unknown), and PFHxS (98%) were pur-
chased from Interchim (Montlucon, France).
13C4-Labeled PFOA, 13C4-labeled PFOS, and
13C5-labeled PFNA were from Wellington
Laboratories (Guelph, Ontario, Canada).
Extraction. The serum and milk samples
were extracted using weak anion exchange,
solid-phase extraction (Waters Oasis WAX,
Milford, MA, USA) based on the method by
Taniyasu and colleagues (Taniyasu et al.
2005). Internal standards (13C4-PFOA and
13C4-PFOS) and 2 mL formic acid/water (1:1)
were added to 1 mL milk and 0.5 mL serum.
The solution was sonicated for 15 min and
centrifuged at 10,000 × g for 30 min. The
supernatant was extracted and the perfluori-
nated compounds were eluted with 1 mL 2%
ammonium hydroxide in methanol, after
washing the column with 2 mL sodium
acetate buffer solution, pH 4, and 2 mL 40%
methanol in water. Sodium acetate buffer was
not used for the serum samples. The ﬁnal vol-
ume for the serum extracts was 500 μL. Milk
extracts were further evaporated to 30 μL, and
20 μL 2-mM ammonium acetate in water was
added. Finally, ﬁltration through a Microcon
YM-3 centrifugal filter (Millipore, Billerica,
MA, USA) was conducted at 14,000 × g for
30 min. Performance standards, 13C5-PFNA
and 7H-PFHpA, were added to both milk and
serum extracts immediately before injection. 
Analysis. We performed the analysis using
an Agilent 1100 HPLC system coupled to an
Agilent 1100 mass spectrometric detector
(Agilent, Waldbronn, Germany) with an
atmospheric electrospray interface operating in
negative ion mode. Separation was performed
on a Discovery HS C18 (50 mm length, 2.1
mm inner diameter, 3 μm particles, 120 Å
pore size) column with a guard column of the
same material (20 mm length, 2.1 mm inner
diameter, 3 μm particles, 120 Å pore size)
(Supelco, Bellefonte PA, USA). Both columns
were kept at 40°C. An extra guard column
(HyperCarb graphitic carbon, 4 mm length,
10 mm inner diameter, 5 μm particle size;
Termo Hypersil-Keystone, Bellefonte PA,
USA) was inserted between the pump and
injector to remove any ﬂuorochemicals origi-
nating from the HPLC system. Injection vol-
ume was 10 μL and the flow rate was set to
300 μL/min. The mobile phases consisted of
2 mM ammonium acetate in methanol and
2 mM ammonium acetate in water. HPLC
gradient and MS settings have been described
in detail elsewhere (Karrman et al. 2005). 
Quality assurance. Quantiﬁcation was per-
formed using the internal standard method
with standards dissolved in 35% methanol in
water. We used 13C4-PFOS as internal standard
for the sulfonates and PFOSA, and 13C4-PFOA
for the carboxylates. We used 13C5-PFNA and
7H-PFHpA to monitor the recovery of the
internal standards. The recovery was on aver-
age 67%, within 50–130% for 78% of all milk
samples and within 84–97% for all serum sam-
ples. An overview of the method performance
is given in Table 2. Recoveries were evaluated
by three or ﬁve replicate fortiﬁcations to a low-
contaminated serum sample and a breast milk
sample containing PFCs below the detection
limit. Average recoveries were > 50% for all
compounds except for PFOSA, PFDA,
PFUnDA, and PFDoDA (34–47%) and the
coefficient of variation (CV) was 2–27% for
multiple determinations. Containers used for
storage of milk and serum samples were
extracted with methanol and did not show
traces of the target compounds. Procedural
blank trace levels were detected for PFOA,
PFOS, and PFNA (Table 3). In the case of
blank levels, the mean blank signal plus 3 SDs
of multiple blank injections were subtracted
from the calculated concentrations in the sam-
ples. A blank corrected concentration was
reported provided that the blank level was
≤ 50% of the uncorrected concentration.
Detection limits for serum and breast milk
were 0.1–1.1 ng/mL and 0.005–0.209 ng/mL,
respectively. The selectivity of the mass
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Table 1. Overview of milk and serum samples, col-
lected from primiparous women in Sweden. 
Year of 
Region collection No.a Age (years)b
Composite milk 
Uppsala 1996 25 29 (21–41)
Uppsala 1997 69 28 (21–38)
Uppsala 1998 90 29 (22–37)
Uppsala 1999 23 28 (22–36)
Uppsala 2000 30 30 (21–37)
Göteborg 2001 37 30 (19–40)
Uppsala 2002 31 30 (24–37)
Lund 2003 37 29 (25–39)
Lycksele 2003–2004 39 27 (20–36)
Individual milk and serum 
Uppsala 2004 — 29
Uppsala 2004 — 24
Uppsala 2004 — 29
Uppsala 2004 — 29
Uppsala 2004 — 28
Uppsala 2004 — 30
Uppsala 2004 — 31
Uppsala 2004 — 27
Uppsala 2004 — 33
Uppsala 2004 — 28
Uppsala 2004 — 22
Uppsala 2004 — 29
aNumber of individual samples in the composite sample.
bMedian (minimum–maximum). 
Table 2. Performance of the methods for extracting human serum and milk samples. 
Percent of recovery (CV) Detection limit (ng/mL)a Blank concentration (ng/mL)b
Compound Serum (n = 5) Milk (n = 3) Serum Milk Serum Milk
PFBuS 85 (2) 79 (4) 0.7 0.05 — —
PFHxS 89 (3) 81 (3) 0.2 0.01 — —
PFOS 82 (5) 83 (3) 0.2 0.005 — 0.050
THPFOS 53 (4) 51 (5) 1.1 0.07 — —
PFDS 39 (9) 72 (4) 0.2 0.04 — 0.084
PFHxA 82 (3) 80 (2) 0.7 0.1 — —
PFHpA 82 (2) 84 (4) 0.3 0.1 — —
PFOA 89 (2) 82 (4) 0.4 0.01 0.5 0.209
PFNA 95 (2) 77 (2) 0.2 0.005 — —
PFDA 56 (5) 43 (27) 0.1 0.008 — 0.014
PFUnDA 47 (7) 38 (3) 0.2 0.005 — 0.008
PFDoDA 41 (11) 39 (5) 0.5 0.005 — —
PFOSA 47 (4) 34 (0) 0.1 0.007 — —
Abbreviations: —, below the detection limit; CV, coefﬁcent of variation. Values for detection limit and blank concentration
are from multiple experiments.
aNot including eventual blank concentrations. bMean ± 3 SD of detected signal from injecting 10 µL of a procedural blank.spectrometry (MS) analysis was verified by
triple quadrupole mass spectrometry (MS/MS)
analysis. All breast milk samples (1 mL) were
extracted in duplicates. The ﬁrst sample extract
was evaporated to 50 μL and injected on the
LC-MS system (10 μL). The second extract
was kept at 500 μL, of which 200 μL was
injected on a column-switching LC system
connected to a triple quadrupole MS system
(Micromass QuattroII, Altrincham, UK).
Further quality assurance was taken by success-
ful participation in the first interlaboratory
study on PFCs (Van Leeuwen et al. 2006). 
Results 
A summary of the results of 12 individual
matched milk and serum samples is given in
Table 3. Highest mean serum concentration
was obtained for PFOS (20.7 ng/mL) fol-
lowed by PFHxS (4.7 ng/mL), PFOA
(3.8 ng/mL), PFNA (0.80 ng/mL), PFDA
(0.53 ng/mL), PFUnDA (0.40 ng/mL), and
PFOSA (0.24 ng/mL). PFDS was detected in
only one serum sample (0.33 ng/mL). Of the
eight PFCs found in the serum samples, ﬁve
were detected in the matched milk samples at
the current detection limits. PFOS and
PFHxS were detected in all milk samples at
mean concentrations of 0.201 ng/mL and
0.085 ng/mL, respectively. PFOSA was
detected in eight milk samples with a mean
concentration of 0.013 ng/mL, and PFNA
was detected in two milk samples (0.020 and
0.014 ng/mL). Similar PFC occurrence and
levels were found in the milk composite sam-
ples collected during the 8 years between
1996 and 2004 (Table 4). 
Milk levels were lower compared with the
matched serum levels on a volume basis
(nanograms per milliliter). The mean ratio
between milk and serum (M:S) concentration
was 0.01:1 for PFOS, 0.02:1 for PFHxS, and
0.07:1 for PFOSA (Table 3). The M:S ratios
for PFOA and PFNA are uncertain because
only one and two milk samples, respectively,
contained levels above the detection limit.
Simple regression analysis and the Spearman’s
correlation test of the matched serum and
milk samples show a significant association
(r2 = 0.7–0.8, p < 0.05) between levels of
PFOS and PFHxS in serum and milk
(Figure 1). The percentage contribution of
each of PFHxS, PFOS, PFOSA, and PFNA
to the total concentration in serum and milk
is given in Figure 2. 
The limits of detection (LOD) in human
milk were between 0.005 and 0.010 ng/mL,
except for PFHxA and PFHpA, which were
an order of magnitude higher (0.1 ng/mL)
(Table 2). A relatively high blank level was
obtained for PFOA (0.209 ng/mL). PFOA is
reported in only one milk sample as a con-
sequence of the high blank level and the
quantiﬁcation criteria.
Discussion
The serum levels in the present study are
similar to or lower than the levels found in a
previous study on 17 Swedish human plasma
samples collected in 1998–2000 from men
and women (Karrman et al. 2004). The
Swedish PFOS and PFOA blood levels are
similar to levels in, for example, Canada,
Australia, and some less-industrialized regions
in Japan, but somewhat lower than reported
blood levels in the United States (Harada et al.
2004; Karrman et al. 2006a; Kubwabo et al.
2004; Olsen et al. 2003). 
Only one study originating from China
has previously reported levels of several
PFCs in human milk. The Swedish levels are
comparable to human milk from China except
for those for PFOSA, which was not included
in the Chinese study (So et al. 2006). In addi-
tion to detected PFCs in the present study,
PFHpA, PFDA, and PFUnDA were also
found in human milk from China. 
PFOSA was frequently detected in the
milk samples, unlike PFNA, PFDA and
PFUnDA, even though the latter were detected
at higher concentrations in the serum samples.
This is most likely caused by the fact that
PFOSA concentrations in plasma have been
found to be only about 20% of the whole
blood concentration on a volume basis
(Karrman et al. 2006b). The total blood con-
centration of PFOSA available for excretion to
milk is therefore about ﬁve times higher than
the measured concentration in serum. The
M:S ratio for PFOSA should therefore be close
to that of PFOS if nearly all PFOSA were dis-
tributed to serum. The serum and milk pattern
suggests that PFHxS is excreted to milk in a
higher degree than PFOS and PFOSA. A pref-
erential excretion of shorter, less hydrophobic
PFCs is a possible explanation of the observed
pattern, but could not be concluded in the pre-
sent study because of the limited number of
matched milk and serum samples.
The presented linear relationship between
serum and milk levels suggests a partitioning
process, which can be predicted from the
PFC blood concentration on a volume basis.
The steeper slope of PFHxS demonstrates the
higher partition than PFOS to milk (Figure
1). The association between milk and serum
concentrations could not be seen for PFOSA
(r2 < 0.1). The PFOSA ratio between milk
and serum can be inﬂuenced by several para-
meters. First, it has been suggested that
PFOSA can degrade to PFOS in biologic sys-
tems (Tomy et al. 2003), which might affect
the ratio between milk and serum. Second,
PFOSA is partly lost during the separation of
the red blood cells, which makes serum a
poor matrix for determining PFOSA blood
concentrations. Finally, relatively more milk
and serum samples had levels of PFOSA close
to the detection limit.
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Table 3. Levels (ng/mL) of seven PFCs in matched milk and serum samples from 12 primiparous Swedish
women, 2004.
PFHxS PFOS PFOSA PFOA PFNA PFDA PFUnDA
Serum
No. > LOD 12 12 9 12 12 12 12
Range 1.8–11.8 8.2–48.0 < 0.10–0.49 2.4–5.3 0.43–2.5 0.27–1.8 0.20–1.5
Mean 4.7 20.7 0.24 3.8 0.80 0.53 0.40
SD 2.9 10.5 0.16 1.0 0.55 0.41 0.35
Median 4.0 18.7 0.19 3.8 0.63 0.43 0.28
Milk
No. > LOD 12 12 8 1a 20 0
Range 0.031–0.172 0.060–0.470 < 0.007–0.030 < 0.209b–0.492 < 0.005–0.020 < 0.008 < 0.005
Mean 0.085 0.201 0.013 NA 0.017 NA NA
SD 0.047 0.117 0.009 NA NA NA NA
Median 0.070 0.166 0.010 NA NA NA NA
M:S 0.02:1 0.01:1 0.07:1 0.12:1 0.01:1 NA NA
CV 28 38 67 NA 52 NA NA
NA, not applicable. 
aEleven additional samples were above the detection limit (0.01 ng/mL) but the blank level was > 50% of the detected con-
centrations (blank level 0.209 ng/mL). bBlank level.
Table 4. Levels (ng/mL) of 5 PFCs in composite milk samples from primiparous Swedish women.
Region Year of collection PFHxS PFOA PFNA PFOS PFOSA
Uppsala 1996 0.037 < 0.209a 0.028 0.209 < 0.007
Uppsala 1997 0.030 < 0.209a < 0.005 0.207 < 0.007
Uppsala 1998 0.040 < 0.209a < 0.005 0.219 < 0.007
Uppsala 1999 0.044 < 0.209a < 0.005 0.213 < 0.007
Uppsala 2000 0.028 < 0.209a 0.019 0.191 < 0.007
Göteborg 2001 0.028 < 0.209a < 0.005 0.258 < 0.007
Uppsala 2002 0.051 < 0.209a < 0.005 0.194 < 0.007
Lund 2003 0.025 < 0.209 < 0.005 0.153 < 0.007
Lycksele 2003–2004 0.016 < 0.209 0.020 0.123 < 0.007
aLevels were above the detection limit (0.01 ng/mL) but the blank level was > 50% of the detected concentrations (blank
level 0.209 ng/mL).For more fat-soluble, persistent organo-
halogens, the levels in blood and milk are
about the same when calculated on a fat basis
and with a steady state assumption. On a vol-
ume basis, the ratio of lipophilic compounds
in whole blood and milk is approximately
1:10, because of the higher lipid content in
milk than in blood (Jensen and Slorach
1991). The lactational transfer of PFCs may
be more similar to that of heavy metals. For
example, the concentration of lead in milk
has been found to be 5–10 times lower than
that in blood (Jensen and Slorach 1991).
Perﬂuorinated acids are generally believed to
bind to serum albumin (Jones et al. 2003). It
has been demonstrated that serum albumin in
plasma has a large binding capacity for PFOA
(6–9 binding sites per molecule and millimo-
lar concentration in plasma) and the free frac-
tion of PFOA in plasma was estimated to be
< 5% (Han et al. 2003). The reason for the
relatively higher PFC concentration in human
serum than in milk is unknown. 
Excretion of PFCs into milk may be
accomplished by two ways that have been
identified as transport mechanisms for
chemical contaminants: binding to milk
protein (protein content ∼ 1 g/100 mL milk)
or to the surface of fat (fat content ∼ 4 g/100
mL milk) (Jensen and Slorach 1991). The fat
content in milk fluctuates but does not vary
significantly during the course of lactation,
unlike the total protein content, which was
shown to decrease rapidly during the first
month of lactation. The serum albumin con-
tent of milk was, however, stable during a
6.5-month period of lactation (Lönnerdal
et al. 1976). Assessing the amount of PFCs
transferred and adsorbed by an infant during
the course of lactation involves several
assumptions—for instance, the variation of
PFC concentration in milk with time and the
uptake efficiency of PFCs from milk by the
infant. The total mean PFC concentration of
all detected compounds in the present study
was 32 ng/mL in serum and 0.34 ng/mL in
milk. Hypothetically, a lactation of 600
mL/day and 100% uptake would produce an
exposure burden for an infant (and maternal
excretion) of 203 ng PFCs per day, corre-
sponding to 34 μg PFCs after 6 months,
given a constant PFC concentration in milk
during 6 months. A risk assessment is unfeasi-
ble because of the lack of human hazard
assessment of each of the detected PFCs and
of relevant reference intake levels or concen-
trations to compare with. However, So et al.
(2006) used a reference dose (25 ng/kg/day)
for PFOS estimated by the Environmental
Working Group, based on the end point of
increase in mammary ﬁbroadenomas in a rat
chronic toxicity study (Thayer and Houlihan
2002). Using the same assumptions (milk
consumption 600 g/day, body weight 7 kg),
two milk samples with the highest PFOS con-
centration in our study (0.465 and 0.337
ng/mL) exceed the reference dose and would
therefore constitute a risk to the infant.
However, there are several uncertainties that
need clariﬁcation before any conclusions can
be made. 
This study contributes to PFC exposure
risk assessments for infants, and the evalua-
tion of lactation as an exposure pathway as
well as a way for maternal excretion. Several
studies indicate that females have lower blood
concentrations of several PFCs than do males
(Calafat et al. 2006a; Karrman et al. 2006a;
Olsen et al. 2003). Elimination through lacta-
tion could be one explanation for this obser-
vation. However, a sex difference was
observed also for 2- to 12-year-old children in
the United States (Olsen et al. 2004).
PFOS and PFHxS were detected in com-
posite milk samples collected each year
between 1996 and 2003–2004 from four dif-
ferent regions in Sweden (Table 4). The vari-
ation of PFOS and PFHxS in the composite
samples is remarkably small (a total variation
of 20% and 32% CV, respectively), indicat-
ing that milk levels of PFOS and PFHxS
have been constant in the last 8 years.
Consequently, no clear temporal trend could
be distinguished (Figure 3). However, the
samples from 2001, 2003, and 2003–2004
were from regions different from the rest of
the samples. Possible regional differences in
human PFC levels in Sweden remain yet to
be established. PFOS has been present in the
Swedish environment at least since 1968, and
the levels increased dramatically up to 1997
in guillemot eggs (Holmström et al. 2004).
PFOS-related products were imported in
Sweden until 2002 and will probably be used
for a long period of time [KEMI (Swedish
Chemicals Agency) 2004]. The global pro-
duction of perfluorooctanesulfonyl fluoride
started to decrease in 2001 after the phase-
out decision by the major producer 3M (3M
2000). A possible effect of the actions taken
by governments and producers in terms of
declining environmental and human concen-
trations needs to be monitored for several
years to come because of the persistence of
PFCs [PFOS half-life is approximately
5 years in humans (Olsen et al. 2005a)].
Exposure of perfluorinated chemicals through lactation
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Figure 3. Temporal trend for (A) PFOS and (B) PFHxS in human composite milk samples from different
regions in Sweden, 1996–2004.
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Figure 1. Scatterplot and regression analysis of levels in matched serum and milk samples from
12 Swedish primiparous women (numbered 1–12), 2004. (A) PFOS (M:S ratio, 0.01:1; CV, 38%; y = 0.0092x +
0.0104; r2 = 0.6868). (B) PFOA (M:S ratio, 0.02:1; CV, 28%; y = 0.0144x + 0.0178; r2 = 0.7707). 
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Figure 2. The average contribution (%) of PFOS, PFHxS, PFNA, and PFOSA to the total concentration in
12 matched milk and serum samples from primiparous women in Sweden, 2004.Kärrman et al.
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The relatively low levels of PFCs present
in the human milk samples challenged the
analysis. By reducing the volume of the milk
sample extracts by a factor of 100, required
detection limits were achieved. As a conse-
quence, traces in the procedural blanks were
seen for several of the compounds monitored
(Table 2). A confident quantification of
PFOA in the milk samples was hampered by
a high procedural blank contamination.
PFOA is usually the second highest PFC
found in human blood, except in Korea
where PFOA levels have been reported to
exceed those of PFOS (Kannan et al. 2004).
PFOA contributed up to 36% of the total
PFC content in human milk from China (So
et al. 2006). The selectivity of the single
quadrupole MS method was successfully veri-
ﬁed with triple quadrupole MS/MS analysis.
Qualitative comparison indicated that
MS/MS analysis demonstrated on average
50% higher concentrations compared with
the single quadrupole MS analysis. However,
different preconcentration methods were
used for the different instruments, and the
differences seen between the methods can
be multifactorial.
Conclusions
The PFC level in human milk are about 1%
of the corresponding level in serum. There is
an indication that elimination of PFCs
through lactation is compound-dependent
and partitioning of PFCs into milk seems to
relate to the concentration in maternal blood.
A trend of PFC concentrations in milk
between 1996 and 2004 could not be
observed in the present study. Lactation is a
considerable source of PFC exposure for
infants. The present study indicates that
approximately 200 ng PFCs per day may be
transferred from a lactating mother to the
infant. Reference concentrations as well as
information on the infant’s uptake and excre-
tion of PFCs during the lactation period are
urgently needed for a full risk assessment.
The ubiquitous presence and levels of PFOS
in human milk justiﬁes further monitoring of
this class of contaminants in human milk
worldwide. 
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CORRECTION
In the manuscript originally published
online, in Table 2, some of the values for
the blank concentrations of serum and
milk were incorrect. Figure 1B describes
PFOA, not PFHxS. These errors have been
corrected here.